pyrrolidine has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Baukov, YI; Borisevich, SS; Borozdenko, DA; Chekhonin, VP; Cherkashova, EA; Ezdoglian, AA; Golubev, YV; Gonchar, DI; Gubskiy, IL; Gubsky, LV; Gureev, MA; Kiseleva, NM; Lagunin, AA; Lyakhmun, DN; Namestnikova, DD; Negrebetsky, VV; Shagina, AD; Shmigol, TA; Tarasenko, DV | 1 |
| Choubey, PK; Seth, A; Shrivastava, SK; Tripathi, A; Tripathi, MK | 1 |
| Gadhe, CG; Jeong, KS; Kim, GH; Lee, JY; Lim, EJ; Lim, KS; Lim, SM; Pae, AN; Son, WS; Yang, HK | 1 |
| Abram, M; Doboszewska, U; Kamiński, K; Latacz, G; Lubelska, A; Mogilski, S; Nieoczym, D; Pieróg, M; Socała, K; Szulczyk, B; Wlaź, P | 1 |
| Chlebek, I; Kamiński, K; Obniska, J; Rzepka, S; Wiklik, B | 1 |
| Lee, YH; Lee, YS; Nam, SO; Park, DH; Ryu, JH | 1 |
| Cottens, S; Cumin, F; Ehrhardt, C; Kosaka, T; Lorthiois, E; Maibaum, J; Ostermann, N; Rigel, DF; Sellner, H; Wagner, T; Webb, RL | 1 |
| Ku, HC; Kuo, YH; Lee, SY; Su, MJ; Yang, KC | 1 |
| Bhatt, UR; Bleasby, K; Chabin, RM; Chen, D; Chen, Q; Colletti, SL; Garcia-Calvo, M; Geissler, WM; Graham, TH; Hale, JJ; He, H; Lassman, ME; Liu, W; Pinto, S; Shen, DM; Shen, HC; Shen, Z; Tata, JR; Tong, X; Tung, EC; Verras, A; Xie, D; Xiong, Y; Xu, S | 1 |
| Baker, S; Beebe, X; Boyce-Rustay, JM; Darczak, D; Donnelly-Roberts, D; Franklin, P; Gomez, E; Henry, RF; Janis, R; Jarvis, MF; Kage, KL; Marsh, KC; Milicic, I; Namovic, M; Niforatos, W; Scott, VE; Simler, G; Stewart, AO; Surowy, C; Swensen, A; Vortherms, T; Wetter, JM; Zhong, C; Zhu, CZ | 1 |
| Bialer, M; Finnell, RH; Isoherranen, N; Merriweather, M; Roeder, M; Schurig, V; Spiegelstein, O; Triplett, AA; Yagen, B; Zhang, J | 1 |
11 other study(ies) available for pyrrolidine and Disease Models, Animal
| Article | Year |
|---|---|
A Novel Phenylpyrrolidine Derivative: Synthesis and Effect on Cognitive Functions in Rats with Experimental Ishemic Stroke.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cognition; Disease Models, Animal; Glutamic Acid; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Molecular Docking Simulation; Neurons; Neuroprotective Agents; Primary Cell Culture; Pyrrolidines; Rats; Rats, Wistar; Stroke | 2021 |
Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Male; Maze Learning; Molecular Structure; Neuroprotective Agents; Oxadiazoles; Peptide Fragments; Pyrrolidines; Rats; Rats, Wistar; Structure-Activity Relationship | 2021 |
Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Disease Models, Animal; HEK293 Cells; Humans; Ligation; Male; Mice; Mice, Knockout; Molecular Structure; Neuralgia; Pyrrolidines; Rats; Rats, Sprague-Dawley; Spinal Nerves; Streptozocin | 2018 |
KA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro Characterization.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Male; Mice; Molecular Structure; Neuralgia; Pentylenetetrazole; Pyrrolidines; Seizures | 2019 |
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
Topics: Administration, Oral; Animals; Anticonvulsants; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Drug Design; Electroshock; Humans; Male; Mannich Bases; Mice; Microsomes, Liver; Motor Activity; Pentylenetetrazole; Protein Binding; Pyrrolidines; Rats; Rats, Sprague-Dawley; Seizures; Structure-Activity Relationship | 2013 |
Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Coumarins; Disease Models, Animal; Enzyme Activation; Male; Memory; Memory Disorders; Mice; Mice, Inbred ICR; Protein Binding; Pyrrolidines; Scopoletin; Structure-Activity Relationship | 2014 |
trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
Topics: Animals; Aspartic Acid Proteases; Binding Sites; Crystallography, X-Ray; Disease Models, Animal; Humans; Hydrogen Bonding; Hypertension; Isomerism; Molecular Dynamics Simulation; Oxygen; Protease Inhibitors; Protein Binding; Protein Structure, Tertiary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Structure-Activity Relationship | 2015 |
Modification of Caffeic Acid with Pyrrolidine Enhances Antioxidant Ability by Activating AKT/HO-1 Pathway in Heart.
Topics: Animals; Antioxidants; Caffeic Acids; Cardiotonic Agents; Cell Line; Cell Survival; Disease Models, Animal; Heme Oxygenase-1; Hydrogen Peroxide; Male; Mice; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Neutrophil Infiltration; Oxidative Stress; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Reactive Oxygen Species; Signal Transduction; Ventricular Function | 2016 |
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.
Topics: Amides; Animals; ATP Binding Cassette Transporter, Subfamily B; Benzimidazoles; Biological Transport; Body Weight; Brain; Carboxypeptidases; Disease Models, Animal; Humans; Inhibitory Concentration 50; Mice; Models, Chemical; Obesity; Pyrrolidines; Time Factors | 2012 |
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.
Topics: Acetamides; Analgesics; Animals; Behavior, Animal; Calcium Channel Blockers; Calcium Channels, N-Type; Disease Models, Animal; Male; Pain; Pyrrolidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2012 |
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Topics: Animals; Butyrates; Disease Models, Animal; Female; Fetus; Levetiracetam; Mice; Piracetam; Pregnancy; Prenatal Exposure Delayed Effects; Pyrrolidines; Pyrrolidinones; Teratogens | 2003 |